pcn poster

Posters

Long-term Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Objective: The Orion study (NCT01360866) evaluated the long-term safety, tolerability, and therapeutic effect of brexpiprazole (0.5–3 mg/day), as adjunct to antidepressant treatment, in a...

Aleksandar Skuban , MD;

Claudette Brewer , BA;

Peter Zhang , PhD;

Nanco Hefting , MSc;

Mary Hobart , PhD;

03/01/2019

Long-Term Safety and Maintenance of Efficacy of Solriamfetol (JZP-110) in the Treatment of Excessive Sleepiness in Participants With Narcolepsy or Obstructive Sleep Apnea

INTRODUCTION: Excessive sleepiness (ES) is a prominent symptom of narcolepsy and obstructive sleep apnea (OSA). Solriamfetol, a selective dopamine/norepinephrine reuptake inhibitor, was e...

Colin Shapiro , PhD, FRCPC, MBBCh;

Richard Schwab , MD;

Jean-Louis Pepin , MD;

Jan Hedner , MD;

Mansoor Ahmed , MD;

Nancy Foldvary-Schaefer , DO, MS;

Patrick Strollo , MD;

Geert Mayer , MD;

Kathleen Sarmiento , MD, MPH;

Michelle Baladi , PhD;

Patricia Chandler , MD;

Lawrence Lee , PhD;

Atul Malhotra , MD;

03/01/2019

Long-Term Safety and Efficacy of Sodium Oxybate in Pediatric Patients With Narcolepsy: Evaluation of Depression, Anxiety, and Suicidal Risk

Introduction: Narcolepsy primarily begins in childhood/adolescence. Sodium oxybate (SXB) was evaluated as a treatment for narcolepsy in children/adolescents in a placebo-controlled, rando...

Emmanuel Mignot , MD, PhD;

Michael Strunc , MD;

Judith Profant , PhD, MS;

Y. Grace Wang , MD;

Rupa Parvataneni , MS;

Jed Black , MD;

03/01/2019

RBP-7000 for the Treatment of Schizophrenia: Efficacy and Safety Results From Two Phase III Trials

Introduction: RBP-7000 is a subcutaneously administered, once-monthly, extended-release depot formulation of risperidone designed to achieve therapeutic concentrations without supplementa...

Anne Andorn , MD;

Maurizio Fava , MD, PhD;

John Newcomer , MD;

Sunita Shinde , MD;

Gilbert Muma , PhD;

Christian Heidbreder , PhD;

Jay Graham , BS Pharm, PharmD, RPh;

03/01/2019

Real-World Outcomes Post-Transition to Once-Every-Three-Month Paliperidone Palmitate in Patients With Schizophrenia Within US Commercial and Managed Care Plans

Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) ...

Antoine C. El Khoury , PhD;

Bruno Emond , MA;

Maryia Zhdanava , MA;

Kruti Joshi , MPH, MD;

Charmi Patel , BS , RN, BSN, MPH;

Patrick Lefebvre , MA;

Laura Morrison , MPH;

Dominic Pilon , MA;

Neeta Tandon , MA;

03/01/2019

Long-Term Outcomes With Aripiprazole Lauroxil for the Treatment of Schizophrenia: A 2-Year, Phase 3, Multicenter Extension Study

Background: This post hoc analysis evaluated the trajectory of clinical symptoms and illness severity of outpatients with schizophrenia receiving ongoing long-acting injectable aripiprazo...

03/01/2019

Reality Check in Postpartum Depression: What is Driving Suboptimal Management?

Goal: To assess physicians’ practice patterns in diagnosis, management, and knowledge of emerging treatments for postpartum depression (PPD) Methods: • A 27-question clinical practic...

03/01/2019

Relationship Between Improved Caregiver Burden and Associated Clinical Improvement in Schizophrenia Patients Treated With Paliperidone Palmitate

Objective: Burden is significant for caregivers of patients with schizophrenia. Little is known about the relationship between changes in patient illness severity and functioning and chan...

Kristy Tardieu , BSN, MBA;

Jagadish Gogate , PhD;

Branislav Mancevski , MD;

Edward S. Kim , MD, FACP, MBA;

03/01/2019

Safety and Effectiveness of Long-term Treatment With Lurasidone in Children and Adolescents With Bipolar Depression: Interim Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the long-term safety and efficacy of lurasidone in children and adolescents with bipolar depression. Methods: Patients (10-17 years) with bipolar depression who co...

Antony Loebel , MD;

Robert Goldman , PhD;

Melissa DelBellow , MD;

Andrei Pikalov , MD, PhD;

Ling Deng , PhD;

Michael Tocco , PhD;

03/01/2019

Safety and Efficacy Analysis of Lofexidine From Pooled Phase 3 Studies

Background: Chronic opioid use leads to physical dependence and ultimately to opioid use disorder.  Abrupt discontinuation from opioids results in opioid withdrawal syndrome. Lofexid...

03/01/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products